These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26654696)

  • 1. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
    de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
    Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure.
    Orellana JM; Esteban RJ; Castilla YA; Fernández-Castillo R; Nozal-Fernández G; Esteban MA; García-Valverde M; Bravo J
    Nefrologia; 2016; 36(2):121-5. PubMed ID: 26906451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
    Liu X; Liu Y; Zheng P; Xie X; Li Z; Yang R; Jin L; Mei Z; Chen P; Zhou L
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1555-1569. PubMed ID: 39002024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F; Chen X; Wang C; Zhou A; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
    Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
    PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
    Zawierucha J; Małyszko J; Małyszko J; Dryl-Rydzyńska T; Prystacki T; Marcinkowski W
    Przegl Lek; 2016; 73(4):229-32. PubMed ID: 27526425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
    Bucharles SGE; Barreto FC; Riella MC
    J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
    Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S
    Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.